File downloaded on 2026-11-03
Source URL: https://medicines.health.europa.eu/veterinary/en/600000003688

Galliprant 100 mg - Tablet

Authorised

- Grapiprant

Product identification

Medicine name:
Galliprant 100 mg - Tablet

Active substance:
Grapiprant

Target species:
Dog

Route of administration:
Oral use

Product details

Active substance and strength:
Grapiprant
100.00 milligram(s) / 1.00 Tablet

Pharmaceutical form:
Tablet

Anatomical therapeutic chemical veterinary (ATCvet) codes:
QM01AX

Legal status of supply:
Veterinary medicinal product subject to veterinary prescription

Authorisation status:
Valid

Authorised in:
Austria , Belgium , Bulgaria , Croatia , Cyprus , Czechia , Denmark , Estonia , Finland , France , Germany , Greece , Hungary , Iceland , Ireland , Italy , Latvia , Liechtenstein , Lithuania , Luxembourg , Malta , Netherlands , Norway , Poland , Portugal , Romania , Slovakia , Slovenia , Spain , Sweden , United Kingdom (Northern Ireland)

Available in:
Austria , Belgium , Cyprus , Czechia , Denmark , Finland , France , Germany , Greece , Hungary , Ireland , Italy , Luxembourg , Netherlands , Norway , Poland , Portugal , Romania , Spain , Sweden , United Kingdom (Northern Ireland)

Package description:
Packaging:Bottle (HDPE), Package_size:30 tablets
Packaging:Bottle (HDPE), Package_size:7 tablets

Additional information

Entitlement type:
Marketing Authorisation

Legal basis of product authorisation:
Full application - New active substance (Article 12(3) of Directive No 2001/82/EC)

Marketing authorisation holder:
Elanco GmbH

Marketing authorisation date:
9/01/2018

Manufacturing sites for batch release:
Elanco France S.A.S.

Responsible authority:
European Commission

Authorisation number:
This information is not available for this product.

Date of authorisation status change:
9/01/2018

To consult adverse reactions on veterinary medicinal products please go to www.adrreports.eu/vet

Documents

Combined File of all Documents

English (PDF)
Published on: 26/10/2026
Download

ema-puar-galliprant-v-4222-par-en.pdf